title: The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis.
abstract: BACKGROUND
  Most haemodialysis (HD) centres use anti-hypertensive drugs for the management of hypertension, whereas some centres apply dietary salt restriction strategy. In this retrospective cross-sectional study, we assessed the effectiveness and cardiac consequences of these two strategies.
  
  
  METHODS
  We enrolled all patients from two dialysis centres, who had been on a standard HD programme at the same centre for at least 1 year. All patients underwent echocardiographic evaluation. Clinical data were obtained from patients' charts. Centre A (n = 190) practiced 'salt restriction' strategy and Centre B (n = 204) practiced anti-hypertensive-based strategy. Salt restriction was defined as managing high blood pressure (BP) via lowering dry weight by strict salt restriction and insistent ultrafiltration without using anti-hypertensive drugs.
  
  
  RESULTS
  There was no difference regarding age, gender, diabetes, history of cardiovascular disease and efficiency of dialysis between centres. Antihypertensive drugs were used in 7% of the patients in Centre A and 42% in Centre B (P < 0.01); interdialytic weight gain was significantly lower in Centre A (2.29 +/- 0.83 kgversus 3.31 +/- 1.12 kg, P < 0.001). Mean systolic and diastolic blood pressures were similar in the two centres. However, Centre A had lower left ventricular (LV) mass (indexed for height(2.7): 59 +/- 16 versus 74 +/- 27 g/m(2.7), P < 0.0001). The frequency of LV hypertrophy was lower in Centre A (74% versus 88%, P < 0.001). Diastolic and systolic functions were better preserved in Centre A. Intradialytic hypotension (hypotensive episodes/100 patient sessions) was more frequent in Centre B (11 versus 27, P <0.01).
  
  
  CONCLUSIONS
  This cross-sectional study suggests that salt restriction and reduced prescription of antihypertensive drugs may limit LV hypertrophy, better preserve LV functions and reduce intradialytic hypotension in HD patients.
authors.affiliation: Department of Cardiology, Ege University School of Medicine, Izmir. meral.kayikcioglu@ege.edu.tr
authors.forename: Meral
authors.initials: M
authors.lastname: Kayikcioglu
authors.forename: Murat
authors.initials: M
authors.lastname: Tumuklu
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ozkahya
authors.forename: Oner
authors.initials: O
authors.lastname: Ozdogan
authors.forename: Gulay
authors.initials: G
authors.lastname: Asci
authors.forename: Soner
authors.initials: S
authors.lastname: Duman
authors.forename: Huseyin
authors.initials: H
authors.lastname: Toz
authors.forename: Levent H
authors.initials: LH
authors.lastname: Can
authors.forename: Ali
authors.initials: A
authors.lastname: Basci
authors.forename: Ercan
authors.initials: E
authors.lastname: Ok
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D004039:Diet, Sodium-Restricted; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000517:prevention & control*; D017379:Hypertrophy, Left Ventricular / Q000453:epidemiology / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents